RxDoctor Payments Data

Preston Pate, MD

Pulmonary Disease · Abilene, TXNPI 1144211368

Payments from drug & device makers

$13,433in general payments, 2019–2025

Across 48 payments — averaging $279.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$13K
  • Siemens Medical Solutions USA, Inc.$116
  • Inspire Medical Systems, Inc.$109
  • GSK$109
  • Boehringer Ingelheim$54
  • Sanofi$40
  • plus $124 from 5 others

What the payments were for

  • Travel & lodging$3,07123%
  • Food & beverage$1,1689%
  • Education$9,00067%
  • Gifts$1941%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,433 in reported general payments places this provider in the 75th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$103,915
Medicare patients
633
Services billed
1,184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate16$196,563
Trelegy ElliptaFluticasone/Umeclidin/Vilanter225$161,354
Breztri AerosphereBudesonide/Glycopyr/Formoterol138$91,907
Stiolto RespimatTiotropium Br/Olodaterol Hcl126$60,613
Spiriva RespimatTiotropium Bromide24$11,587
SymbicortBudesonide/Formoterol Fumarate20$8,133
Fluticasone-SalmeterolFluticasone Propion/Salmeterol54$7,115
Bevespi AerosphereGlycopyrrolate/Formoterol Fum14$5,785
Incruse ElliptaUmeclidinium Bromide11$4,312
Albuterol Sulfate HfaAlbuterol Sulfate129$4,065
Wixela InhubFluticasone Propion/Salmeterol29$2,984
BreynaBudesonide/Formoterol Fumarate13$2,046
Ventolin HfaAlbuterol Sulfate17$1,651
Roflumilast14$1,275
Ropinirole Hcl67$621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$54$268,763166 claims
GSKTrelegy Ellipta, Incruse Ellipta$109$165,666236 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$30$105,825172 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Abilene

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →